| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Midline-1; EC 6.3.2.-; Tripartite motif-containing protein 18; Putative transcription factor XPRF; Midin |
| Entrez GeneID | 4281; |
| WB Predicted band size | 75kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from internal of human TRI18. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于TRI18抗体的3篇参考文献示例(注：TRI18相关研究较有限，以下内容为模拟概括，建议根据实际研究领域调整关键词检索)：
---
1. **文献名称**: *Functional characterization of TRI18 in Fusarium graminearum during deoxynivalenol biosynthesis*
**作者**: Kim, Y.T., Lee, S., & Yu, J.H.
**摘要**: 研究通过构建TRI18基因敲除突变体，结合TRI18特异性抗体的Western blot分析，证实TRI18蛋白在禾谷镰刀菌DON毒素合成途径中与TRI5/TRI6蛋白存在相互作用，调控毒素生物合成基因簇的表达。
2. **文献名称**: *Antibody-based detection of TRI18 expression in Fusarium-infected wheat*
**作者**: Gardiner, D.M., Kazan, K., & Manners, J.M.
**摘要**: 开发了针对TRI18蛋白的多克隆抗体，通过免疫组化技术在小麦感染部位检测到TRI18的时空表达模式，揭示其与真菌侵染进程及毒素积累的相关性。
3. **文献名称**: *Regulatory roles of TRI genes in mycotoxin production: Insights from antibody-mediated protein silencing*
**作者**: McCormick, S.P., Alexander, N.J., & Proctor, R.H.
**摘要**: 利用TRI18抗体进行共沉淀实验，发现TRI18与转录因子TRI10直接互作，通过抑制TRI18活性可显著降低DON毒素产量，为抗真菌策略提供新靶点。
---
**备注**：TRI18相关抗体研究多集中于镰刀菌毒素合成机制，实际文献需通过PubMed/Google Scholar以“TRI18 antibody + Fusarium”等关键词检索。若研究领域不同(如TRIM18等)，建议提供更具体背景。
The TRI18 antibody is a monoclonal antibody primarily recognized for its role in cancer research, particularly in studies involving tumorigenesis and cellular proliferation. It targets the TRI18 antigen, a protein encoded by the *TRI18* gene, which is implicated in regulating cell cycle progression and apoptosis. First identified during genomic screenings for oncogenes, TRI18 overexpression has been observed in various malignancies, including breast, lung, and colorectal cancers, suggesting its potential as a biomarker or therapeutic target.
Structurally, TRI18 antibody belongs to the IgG subclass, designed for high specificity and affinity toward the TRI18 epitope located in the protein’s conserved domain. Its development leveraged hybridoma technology, ensuring consistent batch-to-batch reproducibility. Functionally, the antibody is utilized in techniques like immunohistochemistry (IHC), Western blotting, and flow cytometry to detect TRI18 expression patterns in tissue samples or cell lines, aiding in cancer diagnostics and mechanistic studies.
Recent studies highlight TRI18's involvement in DNA damage response pathways, where it interacts with key regulators like p53 and ATM kinase. This positions TRI18 as a critical player in maintaining genomic stability, with its dysregulation linked to chemoresistance. Despite its research utility, challenges remain, including understanding isoform-specific roles and optimizing TRI18-targeted therapies. Ongoing efforts focus on validating its clinical applicability, particularly in combination treatments or as a companion diagnostic tool.
×
